Alice P. Chen

Also affiliated with Dana-Farber Cancer Institute, System Biosciences (United States), National Cancer Institute

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 6%percentile

0.208Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188

Top 78%

0.104DataRank

Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Papers

Driven by 66 papers — median percentile 11. Top paper: “Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W”.

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

Journal of Clinical Oncology(2020)10.1200/jco.19.02630

N/A

4.7DataRank · unranked

179 citations

Fangxin Hong, Christos Vaklavas, Heather H. Cheng, Peter S. Hammerman, Edith P. Mitchell +17 more

Atezolizumab for Advanced Alveolar Soft Part Sarcoma

New England Journal of Medicine(2023)10.1056/nejmoa2303383

N/A

3.3DataRank · unranked

158 citations

Elad Sharon, Geraldine O’Sullivan Coyne, Nancy Moore, Jared C. Foster, James Hu +26 more

Laboratory validation of a clinical metagenomic next-generation sequencing assay for respiratory virus detection and discovery

Nature Communications(2024)10.1038/s41467-024-51470-y

N/A

1.1DataRank · unranked

53 citations

Venice Servellita, Doug Stryke, Emily Kelly, Jessica Streithorst, Nanami Sumimoto +21 more

Sporadic Primary Pheochromocytoma: A Prospective Intraindividual Comparison of Six Imaging Tests (CT, MRI, and PET/CT Using 68Ga-DOTATATE, FDG, 18F-FDOPA, and 18F-FDA)

American Journal of Roentgenology(2021)10.2214/ajr.21.26071

N/A

0.962DataRank · unranked

30 citations

Mayank Patel, Jorge A. Carrasquillo, Alexander Ling, Corina Millo, Babak Saboury +15 more

Selumetinib in adults with NF1 and inoperable plexiform neurofibroma: a phase 2 trial

Nature Medicine(2025)10.1038/s41591-024-03361-4

N/A

0.954DataRank · unranked

41 citations

Geraldine O’Sullivan Coyne, Eva Dombi, Cecilia Tibery, William G. Herrick, Staci Martin +30 more

Efficacy and safety of selumetinib in adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas (KOMET): a multicentre, international, randomised, placebo-controlled, parallel, double-blind, phase 3 study

The Lancet(2025)10.1016/s0140-6736(25)00986-9

N/A

0.707DataRank · unranked

39 citations

Geraldine O’Sullivan Coyne, Pamela L. Wolters, Staci Martin, Said Farschtschi, Ignacio Blanco +38 more

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer

Cancer Chemotherapy and Pharmacology(2022)10.1007/s00280-022-04430-6

N/A

0.560DataRank · unranked

10 citations

Shannon Puhalla, Shalu Pahuja, Fei Ding, Yan Lin, Leonard J. Appleman +30 more

Isoform- and Phosphorylation-specific Multiplexed Quantitative Pharmacodynamics of Drugs Targeting PI3K and MAPK Signaling in Xenograft Models and Clinical Biopsies

Molecular Cancer Therapeutics(2021)10.1158/1535-7163.mct-20-0566

N/A

0.475DataRank · unranked

11 citations

Casey L. Kilpatrick, Melinda G. Hollingshead, Dominic Esposito, Geraldine O’Sullivan Coyne, Andrea M. Gross +7 more

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2 -Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-23-0633

N/A

0.414DataRank · unranked

9 citations

Victoria Wang, Jaime B. Hyman, Petros Grivas, Edith P. Mitchell, John Wright +17 more

Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04600-0

N/A

0.314DataRank · unranked

6 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Shivaani Kummar, Robert Meehan, Larry Rubinstein +13 more

Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04778-5

N/A

0.258DataRank · unranked

4 citations

Shivaani Kummar, Larry Rubinstein, Deborah Wilsker, Nancy Young Moore, Murielle Hogu +16 more

A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2188

Top 78%

0.104DataRank

Top 78%1 citations

Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guoren Yang, Jiadi Wen +80 more

Blood-based assessment of patients with mismatch repair-deficient tumors enrolled in NCI-MATCH Arm Z1D (nivolumab).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2560

Top 78%

0.104DataRank

Top 78%1 citations

Jennifer L. Silhavy, Jennifer S. LoCoco, Biswajit Das, Sorena Rahmanian, Ting-Chia Chang +15 more

Evaluating the indotecan–neutropenia relationship in patients with solid tumors by population pharmacokinetic modeling and sigmoidal Emax regressions

Cancer Chemotherapy and Pharmacology(2023)10.1007/s00280-023-04509-8

N/A

0.104DataRank · unranked

1 citations

Benjamin C. Kennard, Julianne L. Holleran, Nancy Young Moore, Jennifer Zlott, Brian Miller +7 more

Molecular Profiling-Based Assignment of Cancer Therapy (NCI-MPACT): A Randomized Multicenter Phase II Trial

JCO Precision Oncology(2021)10.1200/po.20.00372

N/A

0DataRank · unranked

45 citations

Shivaani Kummar, Nancy Moore, Larry Rubinstein, Yingdong Zhao, P. Mickey Williams +20 more

Advances in the management of alveolar soft part sarcoma

Current Problems in Cancer(2021)10.1016/j.currproblcancer.2021.100775

N/A

0DataRank · unranked

22 citations

Abdul Rafeh Naqash, Hari Sankaran, Alice P. Chen, Geraldine O’Sullivan Coyne

Combination therapy with pazopanib and tivantinib modulates VEGF and c-MET levels in refractory advanced solid tumors

Investigational New Drugs(2021)10.1007/s10637-021-01138-x

N/A

0DataRank · unranked

7 citations

Apurva K. Srivastava, Tony Navas, Fabiola Cecchi, Young Ho Lee, Donald P. Bottaro +11 more

Phase 1 study of Z-Endoxifen in patients with advanced gynecologic, desmoid, and hormone receptor-positive solid tumors

Oncotarget(2021)10.18632/oncotarget.27887

N/A

0DataRank · unranked

9 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Jerry M. Collins, Joel M. Reid, Richard Piekarz +18 more

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.11519

N/A

0DataRank · unranked

50 citations

Geraldine O’Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin Fino +15 more

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3087

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray +13 more

Phase I trial of 5-aza-4’-thio-2’-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.3088

N/A

0DataRank · unranked

5 citations

Geraldine O’Sullivan Coyne, Naoko Takebe, Abdul Rafeh Naqash, Jessica Mukherjee, Ashley Bruns +12 more

Performances of Functional and Anatomic Imaging Modalities in Succinate Dehydrogenase A-Related Metastatic Pheochromocytoma and Paraganglioma

Cancers(2022)10.3390/cancers14163886

N/A

0DataRank · unranked

18 citations

A. Jha, Alexander Ling, Clara Chen, Corina Millo, Mickey J. M. Kuo +13 more

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2145

N/A

0DataRank · unranked

15 citations

Naoko Takebe, Shivaani Kummar, Albiruni R. Abdul Razak, Sant P. Chawla, Suzanne George +13 more

Dose Effect of Mesenchymal Stromal Cell Delivery Through Cardiopulmonary Bypass

The Annals of Thoracic Surgery(2022)10.1016/j.athoracsur.2022.07.035

N/A

0DataRank · unranked

8 citations

Takuya Maeda, Mobolanle A Ayodeji, Shao Ching Tu, Alice P. Chen, May Rajtboriraks +7 more

Extended progression-free survival and long-term safety of nirogacestat in patients with desmoid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11545

N/A

0DataRank · unranked

5 citations

Shivaani Kummar, Seth M. Steinberg, Murielle Hogu, Naoko Takebe, Amisha Shah +3 more

A phase 2 study of anti-PD-L1 antibody (atezolizumab) in grade 2 and 3 chondrosarcoma.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.11528

N/A

0DataRank · unranked

3 citations

Anthony P. Conley, James Lin Chen, Elizabeth J. Davis, Melissa Burgess, Albiruni Ryan Abdul Razak +13 more

Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3026

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Sarah Miller +15 more

1417 Utilization of immune-based response criteria in NCI-CTEP sponsored immunotherapy clinical trials

Regular and Young Investigator Award Abstracts(2022)10.1136/jitc-2022-sitc2022.1417

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, O’Hara Geraldine, Naoko Takebe +2 more

Blood-based detection of actionable alterations from NCI-MATCH patients with no tissue results.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3035

N/A

0DataRank · unranked

0 citations

Amanda Peach, D. A. HOWELL, Biswajit Das, Rini Pauly, Ting-Chia Chang +14 more

Phase II Study of Palbociclib (PD-0332991) in CCND1 , 2 , or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2150

N/A

0DataRank · unranked

20 citations

Fangxin Hong, Richard S. Finn, Angela DeMichele, Edith P. Mitchell, James A. Zwiebel +18 more

A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)

Breast Cancer Research and Treatment(2023)10.1007/s10549-023-06889-0

N/A

0DataRank · unranked

8 citations

Shalu Pahuja, Brian F. Kiesel, Leonard J. Appleman, Fei Ding, Yan Lin +13 more

Cathepsin B knockout confers significant brain protection in the mouse model of stroke

Experimental Neurology(2023)10.1016/j.expneurol.2023.114499

N/A

0DataRank · unranked

6 citations

Yujung Park, Yamileck Olivas, Alice P. Chen, Chunli Liu, Bingren Hu +1 more

A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial

Heliyon(2023)10.1016/j.heliyon.2023.e18680

N/A

0DataRank · unranked

5 citations

Alex P. Toscano, Mohammadhadi Bagheri, Jeffrey Solomon, Laura B. Machado, Patricia LoRusso +4 more

Phase II study of crizotinib in patients with MET amplification and MET exon 14 deletion: Results from NCI-MATCH ECOG-ACRIN trial (EAY131) subprotocols C1 and C2.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3108

N/A

0DataRank · unranked

3 citations

Zihan Wei, David S. Hong, Edith P. Mitchell, James A. Zwiebel, Elad Sharon +15 more

Phase 1 study of indenoisoquinoline LMP744 in adults with relapsed solid tumors and lymphomas.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.3022

N/A

0DataRank · unranked

2 citations

Alice P. Chen, Shivaani Kummar, Murielle Hogu, Larry Rubinstein, Naoko Takebe +15 more

Phase 2 trial of TRC102 (methoxyamine HCl) with temozolomide (TMZ) in patients with granulosa cell ovarian cancer.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5564

N/A

0DataRank · unranked

1 citations

Geraldine O’Sullivan Coyne, Jennifer Zlott, Mohamad A. Salkeni, Naoko Takebe, Ning Ma +12 more

Expanding eligibility criteria for renal and liver function in NCI-sponsored immunotherapy clinical trials.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.e13610

N/A

0DataRank · unranked

1 citations

Alice P. Chen, Martha Kruhm, DAVID S. LOOSE, Geraldine O’Sullivan Coyne, Naoko Takebe +2 more

A phase 2 study of an anti–PD-L1 antibody (atezolizumab) in dedifferentiated chondrosarcoma.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.11533

N/A

0DataRank · unranked

1 citations

Brian Ko, Brian A. Van Tine, Anthony P. Conley, Elizabeth J. Davis, Melissa Burgess +12 more

Data from Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

(2023)10.1158/1078-0432.c.6519480

N/A

0DataRank · unranked

0 citations

Wooin Lee, Alice P. Chen, M. Wade Calcutt, David L. Hachey, W. Vermeulen +6 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Data from Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

(2023)10.1158/1078-0432.c.6530100.v1

Top 100%

0DataRank

Top 100%0 citations

Victoria Wang, Rebecca S. Heist, Scott Kopetz, Edith P. Mitchell, James A. Zwiebel +19 more

Diagnostic performance of [68Ga]DOTATATE PET/CT, [18F]FDG PET/CT, MRI of the spine, and whole-body diagnostic CT and MRI in the detection of spinal bone metastases associated with pheochromocytoma and paraganglioma

European Radiology(2024)10.1007/s00330-024-10652-4

N/A

0DataRank · unranked

19 citations

Mayank Patel, Alexander Ling, Ritu Shah, Clara C. Chen, Corina Millo +19 more

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-0036

N/A

0DataRank · unranked

8 citations

Opeyemi A. Jegede, Mark A. Dickson, Angela DeMichele, Richard Piekarz, Robert J. Gray +15 more

The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers

Cancer Chemotherapy and Pharmacology(2024)10.1007/s00280-024-04651-x

N/A

0DataRank · unranked

1 citations

Naoko Takebe, Alice P. Chen, Shivaani Kummar, Richard Piekarz, Brian F. Kiesel +5 more

A case series of three patients with extensive lung metastatic pheochromocytoma/paraganglioma: evaluation, treatment challenges, and outcomes

Exploration of Endocrine and Metabolic Diseases(2024)10.37349/eemd.2024.00018

N/A

0DataRank · unranked

0 citations

Matthew A. Nazari, A. Jha, Sara Talvacchio, Mickey J. M. Kuo, Mayank Patel +9 more

Correction: A case series of three patients with extensive lung metastatic pheochromocytoma/paraganglioma: evaluation, treatment challenges, and outcomes

Exploration of Endocrine and Metabolic Diseases(2024)10.37349/eemd.2024.00020

N/A

0DataRank · unranked

0 citations

Matthew A. Nazari, A. Jha, Sara Talvacchio, Mickey J. M. Kuo, Mayank Patel +9 more

Concordance between Tumor Tissue and Plasma DNA Genotyping in the NCI-MATCH Trial (EAY131)

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3531

N/A

0DataRank · unranked

3 citations

Filip Jankú, Ying Yuan, Leylah Drusbosky, Alice P. Chen, Xiaofeng Zheng +15 more

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout

Cancers(2025)10.3390/cancers17183068

N/A

0DataRank · unranked

2 citations

David Milewski, Lauren B. Banks, Kelly M. Bailey, Everett J. Moding, Jessica Lake +16 more

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

Cancer Chemotherapy and Pharmacology(2025)10.1007/s00280-025-04844-y

N/A

0DataRank · unranked

1 citations

Shivaani Kummar, Larry Rubinstein, Jennifer Zlott, Geraldine O’Sullivan Coyne, Vincent Chung +17 more

Phase 1 study of recombinant interleukin 15 in combination with nivolumab and ipilimumab in subjects with refractory cancers.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.2617

N/A

0DataRank · unranked

0 citations

Geraldine O’Sullivan Coyne, Ashley Bruns, Larry Rubinstein, Naoko Takebe, Sarah J. Shin +10 more

Phase 2 evaluation of the nilotinib-paclitaxel combination in patients with rare solid tumors: Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors trial 1 (RARE CANCER 1).

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3015

N/A

0DataRank · unranked

0 citations

Andre DeSouza, Jared C. Foster, Naoko Takebe, Geraldine O’Sullivan Coyne, Sarah Miller +8 more

Rapid analysis and response evaluation of combination anti-neoplastic agents in rare tumors (RARE CANCER) trial: RARE 2 talazoparib and temozolomide.

Journal of Clinical Oncology(2025)10.1200/jco.2025.43.16_suppl.3155

N/A

0DataRank · unranked

0 citations

Jennifer Zlott, Jared C. Foster, Sarah J. Shin, Geraldine O’Sullivan Coyne, Naoko Takebe +5 more

National Cancer Institute Cancer Treatment Tolerability Consortium: Current status and future directions

Cancer(2025)10.1002/cncr.35946

N/A

0DataRank · unranked

0 citations

Sandra A. Mitchell, Diane St. Germain, Brennan Parmelee Streck, Alice P. Chen, Lori M. Minasian +1 more

The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design

JNCI Journal of the National Cancer Institute(2020)10.1093/jnci/djz245

N/A

0DataRank · unranked

231 citations

Robert J. Gray, Alice P. Chen, Shuli Li, David R. Patton, Stanley R. Hamilton +35 more

Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment

Cancer Cell(2020)10.1016/j.ccell.2020.10.015

N/A

0DataRank · unranked

104 citations

Naoko Takebe, Toshinori Hinoue, Katherine A. Hoadley, Maria Cardenas, Alina M. Hamilton +41 more

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-3443

N/A

0DataRank · unranked

90 citations

Fengmin Zhao, Marcus Smith Noel, Gregory J. Riely, Edith P. Mitchell, John J. Wright +15 more

Phase I trial of TRC102 (methoxyamine HCl) in combination with temozolomide in patients with relapsed solid tumors and lymphomas

Oncotarget(2020)10.18632/oncotarget.27784

N/A

0DataRank · unranked

20 citations

Shivaani Kummar, Robert Meehan, T. Khanh, Jerry M. Collins, Larry Anderson +20 more

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

The Oncologist(2020)10.1634/theoncologist.2020-0039

N/A

0DataRank · unranked

14 citations

Daniel G. Stover, Maryam B. Lustberg, Abigail B. Shoben, Meng Zhao, Ewa Mrózek +23 more

The MEK inhibitor selumetinib reduces spinal neurofibroma burden in patients with NF1 and plexiform neurofibromas

Neuro-Oncology Advances(2020)10.1093/noajnl/vdaa095

N/A

0DataRank · unranked

38 citations

Eva H. Baker, Andrea M. Gross, Patricia Whitcomb, Andrea Baldwin, Joanne Derdak +9 more

Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology(2020)10.1007/s00280-020-04073-5

N/A

0DataRank · unranked

26 citations

Lihua Wang, Jennifer Zlott, Lamin Juwara, Joseph M. Covey, Jan H. Beumer +18 more

Phase II trial of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886 Hydrogen Sulfate) in adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3612

N/A

0DataRank · unranked

24 citations

Andrea M. Gross, Eva Dombi, Cecilia Tibery, Amanda Carbonell, Naoko Takebe +13 more

Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3506

N/A

0DataRank · unranked

5 citations

Fengmin Zhao, Dustin A. Deming, Edith P. Mitchell, John Joseph Wright, L. Austin Doyle +15 more

Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.3624

N/A

0DataRank · unranked

4 citations

Arjun Mittra, Geraldine O’Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar +15 more

High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-3703

N/A

0DataRank · unranked

91 citations

David Taïeb, Jorge A. Carrasquillo, Daniel A. Pryma, Mayank Patel, Corina Millo +19 more

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-0329

N/A

0DataRank · unranked

71 citations

Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns +19 more

Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-21-2480

N/A

0DataRank · unranked

27 citations

Shivaani Kummar, James Hu, Kristen Ganjoo, Warren A. Chow, Khanh T. Do +17 more

Alice P. Chen

Indexed papers

Top data-sharing exemplar

Papers